Gill Dorit Heart, 62Morristown, NJ

2003023, Dec 18, 2003

Mar 22, 2002

10/104233

Marvin Slepian - Tucson AZ, US
Daniel Yachia - Herzliya-on-Sea, IL
Gill Heart - Tucson AZ, US
Lucjan Hronowski - Bedford MA, US

Harmonia Medical Technologies, Inc.

A61K031/74
A61M031/00

604/500000, 424/078080

Compositions have been developed to reduce or relieve prostatic obstruction. The polymers are used as an endourethral polymer liner. A biodegradable polymer liner layer can be applied to the prostatic urethra by in situ casting, or insertion and shaping of polymeric materials. This liner is preferably formed from structurally supportive, yet eventually biodegradable, polymers which further bolster and support the urethra and peri-urethral tissue during healing, eliminating the need for post-procedure catheter drainage. This step may be optional in specific clinical circumstances. Alternatively, the polymer coating may be applied to the in-situ casted structurally supportive liner, to decrease adhesion and/or provide release of drugs to enhance healing. The compositions can also be used for intra-prostatic void exclusion and space filling with adhesive and/or therapeutic polymers. Voids created as a result of intra-gland “shelling out” are filled with adhesive polymers which facilitate intraprostatic void cavity wall bonding and healing. Polymers are specifically selected to minimize inflammation, secondary bleeding and late fibrotic scarring and stricturing.

2004026, Dec 30, 2004

Dec 24, 2003

10/746311

Gill Heart - Tucson AZ, US
Gideon Tolkowsky - Herzliya, IL
Axel Brisken - Freemont CA, US
Joe Karratt - Millbrae CA, US

A61M031/00

604/500000, 604/022000

Implantable ultrasonic transducer devices and methods are provided to enhance local delivery and tissue uptake of therapeutic substances using phonophoresis. The transducers are adopted to be implanted immediately adjacent or within the target tissue to which the therapeutic substances also are delivered.

2006005, Mar 16, 2006

May 31, 2005

11/140845

Gill Heart - Dunwoody GA, US
Gideon Tolkowsky - Herzliya, IL
Axel Brisken - Freemont CA, US

A61H 1/00

601002000

The transportation of therapeutic substances through internal tissue is enhanced by surgically implanting an ultrasound transducer in immediate proximity to the target tissue and oriented to direct ultrasound having selected characteristics toward the target tissue. The parameters of frequency, mechanical index, pulses per cycle and pulse repetition frequency are selected within defined ranges to cause molecules to be transported at a rate and over a distance substantially greater than by natural diffusion.

2007023, Oct 4, 2007

Apr 28, 2006

11/413652

Axel Brisken - Fremont CA, US
Joseph Karratt - Mountain View CA, US
Gill Heart - Atlanta GA, US

CytoDome, Inc. - Atlanta GA

A61B 17/20

604022000

An implantable ultrasound transducer device is defined by a plurality of coaxially, longitudinally spaced and acoustically isolated transducer elements, controlled as a phased array to define an exposure annulus within tissue disposed about the transducer array. Operation of the array is controlled to enhance transport of therapeutic substance through the tissue while avoiding thermal damage. The array is configured to enable it to be inserted into the tissue and removed from the tissue through a small surgical or natural opening.

2003010, Jun 5, 2003

Dec 5, 2001

10/005853

Marvin Slepian - Tucson AZ, US
Gill Heart - Tucson AZ, US
Lucjan Hronowski - Bedford MA, US

A61K031/74
A61M031/00

424/078080, 604/500000

Compositions have been developed to reduce or relieve prostatic obstruction. The polymers are used as an endourethral polymer liner. A biodegradable polymer liner layer can be applied to the prostatic urethra by in situ casting, or insertion and shaping of preformed materials. This liner is preferably formed from structurally supportive, yet eventually biodegradable, polymers which further bolster and support the urethra and peri-urethral tissue during healing, eliminating the need for post-procedure catheter drainage. This step may be optional in specific clinical circumstances. Alternatively, the polymer coating may be applied to a structural material such as a stent, to decrease adhesion and/or provide release of drugs to enhance healing. The compositions can also be used for intra-prostatic void exclusion and space filling with adhesive and/or therapeutic polymers. Voids created as a result of intragland “shelling out” are filled with adhesive polymers which facilitate intraprostatic void cavity wall bonding and healing. Polymers are specifically selected to minimize inflammation, secondary bleeding and late fibrotic scarring and stricturing.